董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| June Almenoff | 女 | Director | 70 | 5.95万美元 | 未持股 | 2026-03-10 |
| Declan Doogan | 男 | Director | 73 | 4.85万美元 | 未持股 | 2026-03-10 |
| Robyn M. Hunter | 女 | Director | 65 | 6.50万美元 | 未持股 | 2026-03-10 |
| Michael Davidson | 男 | Director | 69 | 5.75万美元 | 未持股 | 2026-03-10 |
| Stuart Rich | 男 | Chief Medical Officer and Director | 76 | 48.12万美元 | 未持股 | 2026-03-10 |
| Christopher T. Giordano | 男 | President and Chief Executive Officer and Director | 52 | 64.48万美元 | 未持股 | 2026-03-10 |
| Gerald T. Proehl | 男 | Director and Chairman | 67 | 8.85万美元 | 未持股 | 2026-03-10 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Stuart Rich | 男 | Chief Medical Officer and Director | 76 | 48.12万美元 | 未持股 | 2026-03-10 |
| Christopher T. Giordano | 男 | President and Chief Executive Officer and Director | 52 | 64.48万美元 | 未持股 | 2026-03-10 |
| Thomas A. McGauley | 男 | Interim Chief Financial Officer | 53 | 未披露 | 未持股 | 2026-03-10 |
| Thomas A. McGauley | 男 | Interim Chief Financial Officer | 54 | 未披露 | 未持股 | 2026-03-10 |
董事简历
中英对照 | 中文 | 英文- June Almenoff
-
June Almenoff自2019年5月15日起担任我们的首席科学官。Almenoff博士在制药行业拥有20多年的经验，曾担任多个高级执行职位，包括被Actavis plc收购的Furiex Pharmaceuticals的总裁兼首席医疗官，Actavis plc现为Allergan plc，其主导产品Viberzi®；，于2015年被FDA批准用于治疗肠易激综合征合并腹泻（IBS-D）。在加入Furiex之前，Almenoff博士曾在GlaxoSmithKline plc工作，在那里她担任多个职责递增的职位。她最近担任众多生物制药公司的董事会成员和顾问。她目前是Harrington Discovery Institute和Brainstorm Cell Therapeutics（NASDAQ:BCLI）的Harrington投资顾问委员会的董事会成员。Almenoff博士拥有史密斯学院（Smith College）的B.A.（优等生），并毕业于西奈山医学院（Mt.Sinai School of Medicine）的医学博士-博士项目。她在斯坦福大学医学中心（Stanford University Medical Center）完成内科住院医师和传染病奖学金培训，并任职于杜克大学医学院（Duke University School of Medicine）的教员，在那里她目前担任兼职。
June Almenoff,has served on Board since November 2021. She is an accomplished biopharma executive with 25 years of senior leadership experience. She currently serves as a Board Director and advisor to management of numerous biopharma companies. Dr. Almenoff previously served, from March 2010 to October 2014, as President and Chief Medical Officer and a member of the board of directors of Furiex Pharmaceuticals, Inc. (previously Nasdaq: FURX) ("Furiex"), which was acquired by Actavis plc (now AbbVie, Inc.) for $1.2 billion in July 2014. Furiex developed eluxadoline (Viberzi), which was approved both in the United States and Europe. Prior to joining Furiex, Dr. Almenoff also served as Chief Medical Officer of RedHill Biopharma Ltd (Nasdaq: RDHL) leading a team that was instrumental in positioning Talicia as a first-line therapy. Earlier in her career, Dr. Almenoff was at GlaxoSmithKline plc (NYSE: GSK) for twelve years, where she held various positions of increasing responsibility, including most recently Vice President in the Clinical Safety organization. While at GlaxoSmithKline, Dr. Almenoff also chaired a PhRMA-FDA working group, and worked in the area of scientific licensing. She also led the development of pioneering data analytics systems, which have been widely adopted by industry regulators to minimize clinical risk for both development and marketed drugs. Dr. Almenoff is currently a member of the investment advisory board of the Harrington Discovery Institute (a venture philanthropy) and an Executive Venture Partner (part-time) at 82 Venture Studios (affiliated with Alloy Therapeutics). She has served as independent Board Director of Tenax Therapeutics, Inc. (Nasdaq: TENX) since 2021 and Actinium Pharmaceuticals, Inc. (NYSE: ATNM) since 2024. She previously served as a member of the board of directors of Brainstorm Therapeutics, Inc. (Nasdaq: BCLI) from 2017 to 2023, Tigenix NV (acquired by Takeda Pharmaceutical Company Limited in August 2018) from 2016 to 2018, and Kurome Therapeutics, Inc. from 2020 to 2021. Dr. Almenoff has strong expertise in translational medicine, clinical development, commercial strategy, and business development across many therapeutic areas. She has led or contributed to numerous regulatory submissions, product approvals and launches. Dr. Almenoff received her B.A. cum laude from Smith College and graduated with AOA honors from the M.D.-Ph.D. program at the Icahn (Mt. Sinai) School of Medicine. She completed post-graduate medical training at Stanford University Medical Center and served on the faculty of Duke University School of Medicine. She is an adjunct Professor at Duke, a Fellow of the American College of Physicians (FACP) and has authored over 70 publications. - June Almenoff自2019年5月15日起担任我们的首席科学官。Almenoff博士在制药行业拥有20多年的经验，曾担任多个高级执行职位，包括被Actavis plc收购的Furiex Pharmaceuticals的总裁兼首席医疗官，Actavis plc现为Allergan plc，其主导产品Viberzi®；，于2015年被FDA批准用于治疗肠易激综合征合并腹泻（IBS-D）。在加入Furiex之前，Almenoff博士曾在GlaxoSmithKline plc工作，在那里她担任多个职责递增的职位。她最近担任众多生物制药公司的董事会成员和顾问。她目前是Harrington Discovery Institute和Brainstorm Cell Therapeutics（NASDAQ:BCLI）的Harrington投资顾问委员会的董事会成员。Almenoff博士拥有史密斯学院（Smith College）的B.A.（优等生），并毕业于西奈山医学院（Mt.Sinai School of Medicine）的医学博士-博士项目。她在斯坦福大学医学中心（Stanford University Medical Center）完成内科住院医师和传染病奖学金培训，并任职于杜克大学医学院（Duke University School of Medicine）的教员，在那里她目前担任兼职。
- June Almenoff,has served on Board since November 2021. She is an accomplished biopharma executive with 25 years of senior leadership experience. She currently serves as a Board Director and advisor to management of numerous biopharma companies. Dr. Almenoff previously served, from March 2010 to October 2014, as President and Chief Medical Officer and a member of the board of directors of Furiex Pharmaceuticals, Inc. (previously Nasdaq: FURX) ("Furiex"), which was acquired by Actavis plc (now AbbVie, Inc.) for $1.2 billion in July 2014. Furiex developed eluxadoline (Viberzi), which was approved both in the United States and Europe. Prior to joining Furiex, Dr. Almenoff also served as Chief Medical Officer of RedHill Biopharma Ltd (Nasdaq: RDHL) leading a team that was instrumental in positioning Talicia as a first-line therapy. Earlier in her career, Dr. Almenoff was at GlaxoSmithKline plc (NYSE: GSK) for twelve years, where she held various positions of increasing responsibility, including most recently Vice President in the Clinical Safety organization. While at GlaxoSmithKline, Dr. Almenoff also chaired a PhRMA-FDA working group, and worked in the area of scientific licensing. She also led the development of pioneering data analytics systems, which have been widely adopted by industry regulators to minimize clinical risk for both development and marketed drugs. Dr. Almenoff is currently a member of the investment advisory board of the Harrington Discovery Institute (a venture philanthropy) and an Executive Venture Partner (part-time) at 82 Venture Studios (affiliated with Alloy Therapeutics). She has served as independent Board Director of Tenax Therapeutics, Inc. (Nasdaq: TENX) since 2021 and Actinium Pharmaceuticals, Inc. (NYSE: ATNM) since 2024. She previously served as a member of the board of directors of Brainstorm Therapeutics, Inc. (Nasdaq: BCLI) from 2017 to 2023, Tigenix NV (acquired by Takeda Pharmaceutical Company Limited in August 2018) from 2016 to 2018, and Kurome Therapeutics, Inc. from 2020 to 2021. Dr. Almenoff has strong expertise in translational medicine, clinical development, commercial strategy, and business development across many therapeutic areas. She has led or contributed to numerous regulatory submissions, product approvals and launches. Dr. Almenoff received her B.A. cum laude from Smith College and graduated with AOA honors from the M.D.-Ph.D. program at the Icahn (Mt. Sinai) School of Medicine. She completed post-graduate medical training at Stanford University Medical Center and served on the faculty of Duke University School of Medicine. She is an adjunct Professor at Duke, a Fellow of the American College of Physicians (FACP) and has authored over 70 publications.
- Declan Doogan
-
Declan Doogan自2013年9月公司成立以来一直担任公司董事。Doogan博士曾担任Portage Biotech，Inc.的首席执行官兼董事。PTGEF:OTCBB自2013年6月起担任Portage Pharmaceuticals Limited董事，自2007年6月起担任Sosei Group Corporation董事。Doogan博士在主要制药和生物技术领域拥有超过30年的行业经验。他曾担任Pfizer公司的高级副总裁兼全球开发主管。他曾担任Pfizer公司的美国、英国和日本的多种执行职务。2007年离开Pfizer以来，他一直担任小型制药公司的执行职务。Doogan博士曾是Amarin（AMRN:NASDAQ）的首席医疗官和代理首席执行官。他也一直担任Prometheus Laboratories公司（圣地亚哥的分子诊断公司）的首席医疗官。Doogan博士拥有多个董事会任命，主要在制药公司，也曾在哈佛大学公共卫生学院、格拉斯哥大学医学院和北里大学（东京）担任教授。Doogan博士于1975年在格拉斯哥大学（Glasgow University）获得医学学位。他是the Royal College of Physicians和the Faculty of Pharmaceutical Medicine的研究员，持有英国肯特大学（the University of Kent）的科学博士学位。
Declan Doogan has served as a director since February 2021. Dr. Doogan has over 30 years of industry experience in both major pharma and biotech. He was the Senior Vice President and Head of Worldwide Development at Pfizer, where many multibillion-dollar programs were delivered e.g., Viagra, Lipitor and Zoloft. He has held a number of executive positions in Pfizer in the U.S., the U.K. and Japan. Since leaving Pfizer in 2007 he has been engaged in executive roles in small pharma. Declan was CMO and acting CEO of Amarin AMRN: Nasdaq, transforming it from a failing neuroscience company to a vibrant cardiovascular company with a market capitalization of over one billion dollars before his departure. He is Chairman and co-founder of Biohaven BHVN:NYSE and an investor in emerging biotechnology and technology companies. He holds a number of Board appointments, principally in pharma companies, and is also a visiting professor at Glasgow University Medical School. Dr. Doogan received his medical degree from Glasgow University in 1975. He is a Fellow of the Royal College of Physicians and the Faculty Pharmaceutical Medicine and holds a Doctorate of Science at the University of Kent in the U.K. - Declan Doogan自2013年9月公司成立以来一直担任公司董事。Doogan博士曾担任Portage Biotech，Inc.的首席执行官兼董事。PTGEF:OTCBB自2013年6月起担任Portage Pharmaceuticals Limited董事，自2007年6月起担任Sosei Group Corporation董事。Doogan博士在主要制药和生物技术领域拥有超过30年的行业经验。他曾担任Pfizer公司的高级副总裁兼全球开发主管。他曾担任Pfizer公司的美国、英国和日本的多种执行职务。2007年离开Pfizer以来，他一直担任小型制药公司的执行职务。Doogan博士曾是Amarin（AMRN:NASDAQ）的首席医疗官和代理首席执行官。他也一直担任Prometheus Laboratories公司（圣地亚哥的分子诊断公司）的首席医疗官。Doogan博士拥有多个董事会任命，主要在制药公司，也曾在哈佛大学公共卫生学院、格拉斯哥大学医学院和北里大学（东京）担任教授。Doogan博士于1975年在格拉斯哥大学（Glasgow University）获得医学学位。他是the Royal College of Physicians和the Faculty of Pharmaceutical Medicine的研究员，持有英国肯特大学（the University of Kent）的科学博士学位。
- Declan Doogan has served as a director since February 2021. Dr. Doogan has over 30 years of industry experience in both major pharma and biotech. He was the Senior Vice President and Head of Worldwide Development at Pfizer, where many multibillion-dollar programs were delivered e.g., Viagra, Lipitor and Zoloft. He has held a number of executive positions in Pfizer in the U.S., the U.K. and Japan. Since leaving Pfizer in 2007 he has been engaged in executive roles in small pharma. Declan was CMO and acting CEO of Amarin AMRN: Nasdaq, transforming it from a failing neuroscience company to a vibrant cardiovascular company with a market capitalization of over one billion dollars before his departure. He is Chairman and co-founder of Biohaven BHVN:NYSE and an investor in emerging biotechnology and technology companies. He holds a number of Board appointments, principally in pharma companies, and is also a visiting professor at Glasgow University Medical School. Dr. Doogan received his medical degree from Glasgow University in 1975. He is a Fellow of the Royal College of Physicians and the Faculty Pharmaceutical Medicine and holds a Doctorate of Science at the University of Kent in the U.K.
- Robyn M. Hunter
-
RobynM.Hunter于2017年6月26日被任命为公司首席财务官。Hunter女士在一系列行业拥有超过30年的财务和运营经验。在担任公司首席财务官之前，亨特女士于2011年6月至2017年6月担任公司Vice President兼公司财务总监，在那里她实施财务和运营流程，程序和政策，以促进公司执行增长战略。2006年1月至2011年5月，亨特女士担任Schochet Associates的高级副总裁和首席财务官。从2004年8月到2006年1月，Hunter女士担任Indevus Pharmaceuticals的公司财务总监。Hunter从1990年到2004年担任Stackpole Corporation会计经理、Vice President和财务主管等多个职位。Hunter女士持有纽约Schenectady市Union College经济学文学学士学位。
Robyn M. Hunter was appointed as the Company's Chief Financial Officer on June 26 2017. Ms. Hunter has more than 30 years of financial and operational experience in an array of industries. Prior to serving as the Company's CFO, Ms. Hunter served as the Company's Vice President and Corporate Controller from June 2011 until June 2017 where she implemented financial and operational processes, procedures and policies to facilitate the Company's execution of its growth strategy. From January 2006 to May 2011 Ms. Hunter served as Senior Vice President and Chief Financial Officer of Schochet Associates. From August 2004 to January 2006 Ms. Hunter served as the Corporate Controller for Indevus Pharmaceuticals. From 1990 to 2004 Ms. Hunter held several positions from Accounting Manager to Vice President and Treasurer of The Stackpole Corporation. Ms. Hunter holds a Bachelor of Arts degree in Economics from Union College in Schenectady New York. - RobynM.Hunter于2017年6月26日被任命为公司首席财务官。Hunter女士在一系列行业拥有超过30年的财务和运营经验。在担任公司首席财务官之前，亨特女士于2011年6月至2017年6月担任公司Vice President兼公司财务总监，在那里她实施财务和运营流程，程序和政策，以促进公司执行增长战略。2006年1月至2011年5月，亨特女士担任Schochet Associates的高级副总裁和首席财务官。从2004年8月到2006年1月，Hunter女士担任Indevus Pharmaceuticals的公司财务总监。Hunter从1990年到2004年担任Stackpole Corporation会计经理、Vice President和财务主管等多个职位。Hunter女士持有纽约Schenectady市Union College经济学文学学士学位。
- Robyn M. Hunter was appointed as the Company's Chief Financial Officer on June 26 2017. Ms. Hunter has more than 30 years of financial and operational experience in an array of industries. Prior to serving as the Company's CFO, Ms. Hunter served as the Company's Vice President and Corporate Controller from June 2011 until June 2017 where she implemented financial and operational processes, procedures and policies to facilitate the Company's execution of its growth strategy. From January 2006 to May 2011 Ms. Hunter served as Senior Vice President and Chief Financial Officer of Schochet Associates. From August 2004 to January 2006 Ms. Hunter served as the Corporate Controller for Indevus Pharmaceuticals. From 1990 to 2004 Ms. Hunter held several positions from Accounting Manager to Vice President and Treasurer of The Stackpole Corporation. Ms. Hunter holds a Bachelor of Arts degree in Economics from Union College in Schenectady New York.
- Michael Davidson
-
Michael Davidson自2021年1月起担任董事会成员。戴维森博士是芝加哥大学的医学教授和脂质诊所主任。他还担任New Amsterdam Pharma的首席执行官。戴维森博士是脂类学领域的领先专家。他进行了1000多项临床试验，发表了350多篇医学期刊文章，并撰写了三本有关脂类学的书籍。他的研究背景包括药物和营养临床试验，包括对他汀类药物、新型降脂药物和欧米茄-3脂肪酸的广泛研究。Davidson博士创立了芝加哥临床研究中心，该中心成为美国最大的研究站点，并于1996年被Pharmaceutical产品开发收购。此外，他于2008年创立了Omthera Pharmaceuticals，该公司于2013年被阿斯利康（AstraZeneca）以4.4亿美元收购，最近，他担任Corvidia Therapeutics的创始首席执行官/CSO，该公司于2020年被Novo Nordisk以高达21亿美元的价格收购。Davidson博士获得了内科，心脏病学和临床脂类学的董事会认证。2010年至2011年，他担任美国国家血脂协会主席，被美国糖尿病协会评为过去15年来美国最好的医生之一，并于2010年被评为年度之父。他也是纳斯达克上市的Caladrius Bioscience的董事会成员。
Michael Davidson has served as Chief Executive Officer and executive director since November 2022. Dr. Davidson served NewAmsterdam Pharma as its Chief Executive Officer and an executive director from Augt 2020 to November 2022. Prior to joining NewAmsterdam Pharma, Dr. Davidson was the founder and Chief Executive Officer of Corvidia Therapeutics, Inc. from January 2016 until April 2018 and the Chief Science/Medical Officer from April 2018 until July 2020, when Corvidia was acquired by Novo Nordisk A/S for up to $2.1 billion. Dr. Davidson, who is a leading expert in the field of lipidology and was named in The Best Doctors in America for the past 15 years, is also currently a professor of medicine and director of the lipid clinic at the University of Chicago. Dr. Davidson co founded and served as the Chief Medical Officer of Omthera Pharmaceuticals, Inc. in 2008, which was later acquired by AstraZeneca Pharmaceuticals in 2013 for up to $443 million. His research background encompasses both pharmaceutical and nutritional clinical trials including extensive research on statins, novel lipid loring drugs, and omega 3 fatty acids. Dr. Davidson is board certified in internal medicine, cardiology, and clinical lipidology and served as President of the National Lipid Association from 2010 to 2011. Dr. Davidson currently serves on the board of directors of Tenax Therapeutics, Inc. (Nasdaq: TENX), and BioAge Labs, Inc. (Nasdaq: BIOA). Dr. Davidson also serves on the boards of f private biotechnology companies, Sonothera, Jocasta Neuroscience and Abcentra. Dr. Davidson received his B.A. and M.S. from Northstern University and his M.D. from The Ohio Stae University School of Medicine. - Michael Davidson自2021年1月起担任董事会成员。戴维森博士是芝加哥大学的医学教授和脂质诊所主任。他还担任New Amsterdam Pharma的首席执行官。戴维森博士是脂类学领域的领先专家。他进行了1000多项临床试验，发表了350多篇医学期刊文章，并撰写了三本有关脂类学的书籍。他的研究背景包括药物和营养临床试验，包括对他汀类药物、新型降脂药物和欧米茄-3脂肪酸的广泛研究。Davidson博士创立了芝加哥临床研究中心，该中心成为美国最大的研究站点，并于1996年被Pharmaceutical产品开发收购。此外，他于2008年创立了Omthera Pharmaceuticals，该公司于2013年被阿斯利康（AstraZeneca）以4.4亿美元收购，最近，他担任Corvidia Therapeutics的创始首席执行官/CSO，该公司于2020年被Novo Nordisk以高达21亿美元的价格收购。Davidson博士获得了内科，心脏病学和临床脂类学的董事会认证。2010年至2011年，他担任美国国家血脂协会主席，被美国糖尿病协会评为过去15年来美国最好的医生之一，并于2010年被评为年度之父。他也是纳斯达克上市的Caladrius Bioscience的董事会成员。
- Michael Davidson has served as Chief Executive Officer and executive director since November 2022. Dr. Davidson served NewAmsterdam Pharma as its Chief Executive Officer and an executive director from Augt 2020 to November 2022. Prior to joining NewAmsterdam Pharma, Dr. Davidson was the founder and Chief Executive Officer of Corvidia Therapeutics, Inc. from January 2016 until April 2018 and the Chief Science/Medical Officer from April 2018 until July 2020, when Corvidia was acquired by Novo Nordisk A/S for up to $2.1 billion. Dr. Davidson, who is a leading expert in the field of lipidology and was named in The Best Doctors in America for the past 15 years, is also currently a professor of medicine and director of the lipid clinic at the University of Chicago. Dr. Davidson co founded and served as the Chief Medical Officer of Omthera Pharmaceuticals, Inc. in 2008, which was later acquired by AstraZeneca Pharmaceuticals in 2013 for up to $443 million. His research background encompasses both pharmaceutical and nutritional clinical trials including extensive research on statins, novel lipid loring drugs, and omega 3 fatty acids. Dr. Davidson is board certified in internal medicine, cardiology, and clinical lipidology and served as President of the National Lipid Association from 2010 to 2011. Dr. Davidson currently serves on the board of directors of Tenax Therapeutics, Inc. (Nasdaq: TENX), and BioAge Labs, Inc. (Nasdaq: BIOA). Dr. Davidson also serves on the boards of f private biotechnology companies, Sonothera, Jocasta Neuroscience and Abcentra. Dr. Davidson received his B.A. and M.S. from Northstern University and his M.D. from The Ohio Stae University School of Medicine.
- Stuart Rich
-
Stuart Rich自2021年1月起担任我们的首席医疗官，自2021年2月起担任董事。Rich博士从PHPM加入公司，他是该公司的联合创始人，并于2018年10月至2021年1月担任首席执行官兼董事。在加入PHPM之前，从2003年10月到2004年12月，Rich博士担任United Therapeutics的兼职首席医疗官。里奇博士目前担任西北大学范伯格医学院的医学教授，并担任英国慈善机构布鲁姆心血管研究所和美国慈善机构心血管医学与研究基金会的肺血管疾病计划主任。在西北大学之前，里奇医生是医学教授。从1980年7月到1996年7月，担任芝加哥伊利诺伊大学医学院心脏科科长，从1996年7月到2004年9月，担任拉什大学医学院拉什心脏研究所的医学教授。2004年9月至2015年7月，担任芝加哥大学普里茨克医学院心脏病学部分的医学教授。里奇博士在伊利诺伊大学获得生物学学士学位，在洛约拉大学斯特里奇医学院获得医学博士学位，并在华盛顿圣路易斯大学完成了医学住院医师学位，在芝加哥大学获得了心脏病学奖学金。
Stuart Rich has served as Chief Medical Officer since January 2021 and a director since February 2021. Dr. Rich joined the Company from PHPM, where he was a co-founder and held the positions of Chief Executive Officer and Director from October 2018 until January 2021. Prior to PHPM, Dr. Rich served as the Chief Medical Officer part-time of United Therapeutics from October 2003 until December 2004. Dr. Rich currently serves as Professor of Medicine at Northwestern University Feinberg School of Medicine and as Director of the Pulmonary Vascular Disease Program at the Bluhm Cardiovascular Institute, a U.K. based charity, and of the Cardiovascular Medical and Research Foundation, a U.S. based charity. Prior to Northwestern University, Dr. Rich was the Professor of Medicine and Chief of the Section of Cardiology at the University of Illinois College of Medicine in Chicago from July 1980 until July 1996 was Professor of Medicine at the Rush Heart Institute of the Rush University School of Medicine from July 1996 until September 2004 and was Professor of Medicine at the Section of Cardiology of the University of Chicago Pritzker School of Medicine from September 2004 until July 2015. Dr. Rich received his B.S. in Biology at the University of Illinois and his M.D. at Loyola University Stritch School of Medicine, and he completed his residency in medicine at the Washington University of St. Louis and his fellowship in cardiology at the University of Chicago. - Stuart Rich自2021年1月起担任我们的首席医疗官，自2021年2月起担任董事。Rich博士从PHPM加入公司，他是该公司的联合创始人，并于2018年10月至2021年1月担任首席执行官兼董事。在加入PHPM之前，从2003年10月到2004年12月，Rich博士担任United Therapeutics的兼职首席医疗官。里奇博士目前担任西北大学范伯格医学院的医学教授，并担任英国慈善机构布鲁姆心血管研究所和美国慈善机构心血管医学与研究基金会的肺血管疾病计划主任。在西北大学之前，里奇医生是医学教授。从1980年7月到1996年7月，担任芝加哥伊利诺伊大学医学院心脏科科长，从1996年7月到2004年9月，担任拉什大学医学院拉什心脏研究所的医学教授。2004年9月至2015年7月，担任芝加哥大学普里茨克医学院心脏病学部分的医学教授。里奇博士在伊利诺伊大学获得生物学学士学位，在洛约拉大学斯特里奇医学院获得医学博士学位，并在华盛顿圣路易斯大学完成了医学住院医师学位，在芝加哥大学获得了心脏病学奖学金。
- Stuart Rich has served as Chief Medical Officer since January 2021 and a director since February 2021. Dr. Rich joined the Company from PHPM, where he was a co-founder and held the positions of Chief Executive Officer and Director from October 2018 until January 2021. Prior to PHPM, Dr. Rich served as the Chief Medical Officer part-time of United Therapeutics from October 2003 until December 2004. Dr. Rich currently serves as Professor of Medicine at Northwestern University Feinberg School of Medicine and as Director of the Pulmonary Vascular Disease Program at the Bluhm Cardiovascular Institute, a U.K. based charity, and of the Cardiovascular Medical and Research Foundation, a U.S. based charity. Prior to Northwestern University, Dr. Rich was the Professor of Medicine and Chief of the Section of Cardiology at the University of Illinois College of Medicine in Chicago from July 1980 until July 1996 was Professor of Medicine at the Rush Heart Institute of the Rush University School of Medicine from July 1996 until September 2004 and was Professor of Medicine at the Section of Cardiology of the University of Chicago Pritzker School of Medicine from September 2004 until July 2015. Dr. Rich received his B.S. in Biology at the University of Illinois and his M.D. at Loyola University Stritch School of Medicine, and he completed his residency in medicine at the Washington University of St. Louis and his fellowship in cardiology at the University of Chicago.
- Christopher T. Giordano
-
Christopher T. Giordano，于2021年7月加入公司，担任首席执行官和董事会成员，并于2021年10月成为总裁兼首席执行官。2018年3月至2021年7月，他担任艾昆纬 Biotech LLC和艾昆纬 MedTech Inc.（一家为医疗器械和小型生物技术公司提供临床和商业综合解决方案的供应商）的总裁，在那里他领导了一个管理临床试验组合的高管团队，在他领导的三年中，该团队管理的临床试验组合从250个活跃项目增长到400个活跃项目。在担任该职务之前，2008年8月至2018年3月，佐丹奴先生在医药外包服务提供商Quintiles Transnational Holdings Inc.（于2016年10月被IMS Health Holdings，Inc.收购，更名为艾昆纬控股有限公司）担任越来越重要的职务，最近担任心血管、肾脏和代谢组的全球副总裁。2001年1月至2008年7月，佐丹奴先生在全球临床研究组织PPD，Inc.担任过各种销售和运营职务。佐丹奴先生拥有圣地亚哥大学的英语学士学位（优等生）和北卡罗来纳大学教堂山分校的英语硕士学位。
Christopher T. Giordano joined the Company as Chief Executive Officer and a member of Board of Directors in July 2021 and became President and Chief Executive Officer in October 2021. From March 2018 to July 2021, he served as President of IQVIA Biotech LLC and IQVIA MedTech Inc., a provider of integrated clinical and commercial solutions to medical device and small biotech companies, where he led an executive team that managed a clinical trial portfolio of several hundred active projects during his three years of leadership. Prior to that role, from Augt 2008 to March 2018, Mr. Giordano held roles of increasing responsibility at Quintiles Transnational Holdings Inc., a provider of pharmaceutical outscing services (acquired by IMS Health Holdings, Inc. in October 2016 to become IQVIA Holdings Inc.), and was most recently Global Vice President of the cardiovascular, renal, and metabolic group. From January 2001 to July 2008, Mr. Giordano served in vario sales and operational roles at PPD, Inc., a global clinical research organization. Mr. Giordano holds a B.A. (summa cum laude) in English from the University of San Diego and a M.A. in English from the University of North Carolina at Chapel Hill. - Christopher T. Giordano，于2021年7月加入公司，担任首席执行官和董事会成员，并于2021年10月成为总裁兼首席执行官。2018年3月至2021年7月，他担任艾昆纬 Biotech LLC和艾昆纬 MedTech Inc.（一家为医疗器械和小型生物技术公司提供临床和商业综合解决方案的供应商）的总裁，在那里他领导了一个管理临床试验组合的高管团队，在他领导的三年中，该团队管理的临床试验组合从250个活跃项目增长到400个活跃项目。在担任该职务之前，2008年8月至2018年3月，佐丹奴先生在医药外包服务提供商Quintiles Transnational Holdings Inc.（于2016年10月被IMS Health Holdings，Inc.收购，更名为艾昆纬控股有限公司）担任越来越重要的职务，最近担任心血管、肾脏和代谢组的全球副总裁。2001年1月至2008年7月，佐丹奴先生在全球临床研究组织PPD，Inc.担任过各种销售和运营职务。佐丹奴先生拥有圣地亚哥大学的英语学士学位（优等生）和北卡罗来纳大学教堂山分校的英语硕士学位。
- Christopher T. Giordano joined the Company as Chief Executive Officer and a member of Board of Directors in July 2021 and became President and Chief Executive Officer in October 2021. From March 2018 to July 2021, he served as President of IQVIA Biotech LLC and IQVIA MedTech Inc., a provider of integrated clinical and commercial solutions to medical device and small biotech companies, where he led an executive team that managed a clinical trial portfolio of several hundred active projects during his three years of leadership. Prior to that role, from Augt 2008 to March 2018, Mr. Giordano held roles of increasing responsibility at Quintiles Transnational Holdings Inc., a provider of pharmaceutical outscing services (acquired by IMS Health Holdings, Inc. in October 2016 to become IQVIA Holdings Inc.), and was most recently Global Vice President of the cardiovascular, renal, and metabolic group. From January 2001 to July 2008, Mr. Giordano served in vario sales and operational roles at PPD, Inc., a global clinical research organization. Mr. Giordano holds a B.A. (summa cum laude) in English from the University of San Diego and a M.A. in English from the University of North Carolina at Chapel Hill.
- Gerald T. Proehl
-
Gerald T. Proehl于2014年12月成为董事、Dermata Therapeutics, Inc.总裁兼首席执行官，并于2021年4月成为Dermata Therapeutics, Inc.董事长。Proehl先生在制药行业拥有30多年的经验。从2002年1月到2014年1月，Proehl先生担任Santarus, Inc.的总裁兼首席执行官，在那里他以26亿美元的价格将Santarus，Inc.出售给了Salix Pharmaceuticals，Inc.。在加入Santarus, Inc.之前，Proehl先生曾在Hoechst Marion Roussel，Inc.工作了14年，担任过各种职务，包括全球营销副总裁。在Hoechst工作期间，他负责多个治疗领域的产品营销，包括心脏病、过敏/呼吸、免疫学和神经学。Proehl先生拥有纽约州立大学科特兰分校的教育学士学位、维克森林大学的运动生理学硕士学位和罗克赫斯特大学的工商管理硕士学位。Proehl先生目前在一家上市公司Tenax Therapeutics, Inc.（纽约证券交易所代码：TENX）担任Shlomo Kramer。由于Proehl先生在其他公司的领导经验以及他创立和经营专业制药公司的历史，他被选为高级管理人员和董事。
Gerald T. Proehl became a director and President and Chief Executive Officer in December 2014 and became Chairman in April 2021. Mr. Proehl has more than 30 years of experience within the pharmaceutical indtry and 21 years of experience as a chief executive officer. From January 2002 until January 2014, Mr. Proehl was President and CEO of Santar, Inc., where he led the sale of Santar, Inc. to Salix Pharmaceuticals, Inc. for $2.6 billion. Prior to Santar, Inc., Mr. Proehl worked for Hoechst Marion Rosel, Inc. for 14 years, where he served in vario capacities, including VP of Global Marketing. While at Hoechst, he was responsible for marketing products in multiple therapeutic areas, including cardiology, allergy/respiratory, immunology, and neurology. Mr. Proehl holds a B.S. in Education from State University of New York at Cortland, an M.A. in Exercise Physiology from Wake Forest University, and an M.B.A. from Rockhurst University. Mr. Proehl currently serves as chairman of the board of one public company, Tenax Therapeutics, Inc. (NYSE: TENX). - Gerald T. Proehl于2014年12月成为董事、Dermata Therapeutics, Inc.总裁兼首席执行官，并于2021年4月成为Dermata Therapeutics, Inc.董事长。Proehl先生在制药行业拥有30多年的经验。从2002年1月到2014年1月，Proehl先生担任Santarus, Inc.的总裁兼首席执行官，在那里他以26亿美元的价格将Santarus，Inc.出售给了Salix Pharmaceuticals，Inc.。在加入Santarus, Inc.之前，Proehl先生曾在Hoechst Marion Roussel，Inc.工作了14年，担任过各种职务，包括全球营销副总裁。在Hoechst工作期间，他负责多个治疗领域的产品营销，包括心脏病、过敏/呼吸、免疫学和神经学。Proehl先生拥有纽约州立大学科特兰分校的教育学士学位、维克森林大学的运动生理学硕士学位和罗克赫斯特大学的工商管理硕士学位。Proehl先生目前在一家上市公司Tenax Therapeutics, Inc.（纽约证券交易所代码：TENX）担任Shlomo Kramer。由于Proehl先生在其他公司的领导经验以及他创立和经营专业制药公司的历史，他被选为高级管理人员和董事。
- Gerald T. Proehl became a director and President and Chief Executive Officer in December 2014 and became Chairman in April 2021. Mr. Proehl has more than 30 years of experience within the pharmaceutical indtry and 21 years of experience as a chief executive officer. From January 2002 until January 2014, Mr. Proehl was President and CEO of Santar, Inc., where he led the sale of Santar, Inc. to Salix Pharmaceuticals, Inc. for $2.6 billion. Prior to Santar, Inc., Mr. Proehl worked for Hoechst Marion Rosel, Inc. for 14 years, where he served in vario capacities, including VP of Global Marketing. While at Hoechst, he was responsible for marketing products in multiple therapeutic areas, including cardiology, allergy/respiratory, immunology, and neurology. Mr. Proehl holds a B.S. in Education from State University of New York at Cortland, an M.A. in Exercise Physiology from Wake Forest University, and an M.B.A. from Rockhurst University. Mr. Proehl currently serves as chairman of the board of one public company, Tenax Therapeutics, Inc. (NYSE: TENX).
高管简历
中英对照 | 中文 | 英文- Stuart Rich
Stuart Rich自2021年1月起担任我们的首席医疗官，自2021年2月起担任董事。Rich博士从PHPM加入公司，他是该公司的联合创始人，并于2018年10月至2021年1月担任首席执行官兼董事。在加入PHPM之前，从2003年10月到2004年12月，Rich博士担任United Therapeutics的兼职首席医疗官。里奇博士目前担任西北大学范伯格医学院的医学教授，并担任英国慈善机构布鲁姆心血管研究所和美国慈善机构心血管医学与研究基金会的肺血管疾病计划主任。在西北大学之前，里奇医生是医学教授。从1980年7月到1996年7月，担任芝加哥伊利诺伊大学医学院心脏科科长，从1996年7月到2004年9月，担任拉什大学医学院拉什心脏研究所的医学教授。2004年9月至2015年7月，担任芝加哥大学普里茨克医学院心脏病学部分的医学教授。里奇博士在伊利诺伊大学获得生物学学士学位，在洛约拉大学斯特里奇医学院获得医学博士学位，并在华盛顿圣路易斯大学完成了医学住院医师学位，在芝加哥大学获得了心脏病学奖学金。
Stuart Rich has served as Chief Medical Officer since January 2021 and a director since February 2021. Dr. Rich joined the Company from PHPM, where he was a co-founder and held the positions of Chief Executive Officer and Director from October 2018 until January 2021. Prior to PHPM, Dr. Rich served as the Chief Medical Officer part-time of United Therapeutics from October 2003 until December 2004. Dr. Rich currently serves as Professor of Medicine at Northwestern University Feinberg School of Medicine and as Director of the Pulmonary Vascular Disease Program at the Bluhm Cardiovascular Institute, a U.K. based charity, and of the Cardiovascular Medical and Research Foundation, a U.S. based charity. Prior to Northwestern University, Dr. Rich was the Professor of Medicine and Chief of the Section of Cardiology at the University of Illinois College of Medicine in Chicago from July 1980 until July 1996 was Professor of Medicine at the Rush Heart Institute of the Rush University School of Medicine from July 1996 until September 2004 and was Professor of Medicine at the Section of Cardiology of the University of Chicago Pritzker School of Medicine from September 2004 until July 2015. Dr. Rich received his B.S. in Biology at the University of Illinois and his M.D. at Loyola University Stritch School of Medicine, and he completed his residency in medicine at the Washington University of St. Louis and his fellowship in cardiology at the University of Chicago.- Stuart Rich自2021年1月起担任我们的首席医疗官，自2021年2月起担任董事。Rich博士从PHPM加入公司，他是该公司的联合创始人，并于2018年10月至2021年1月担任首席执行官兼董事。在加入PHPM之前，从2003年10月到2004年12月，Rich博士担任United Therapeutics的兼职首席医疗官。里奇博士目前担任西北大学范伯格医学院的医学教授，并担任英国慈善机构布鲁姆心血管研究所和美国慈善机构心血管医学与研究基金会的肺血管疾病计划主任。在西北大学之前，里奇医生是医学教授。从1980年7月到1996年7月，担任芝加哥伊利诺伊大学医学院心脏科科长，从1996年7月到2004年9月，担任拉什大学医学院拉什心脏研究所的医学教授。2004年9月至2015年7月，担任芝加哥大学普里茨克医学院心脏病学部分的医学教授。里奇博士在伊利诺伊大学获得生物学学士学位，在洛约拉大学斯特里奇医学院获得医学博士学位，并在华盛顿圣路易斯大学完成了医学住院医师学位，在芝加哥大学获得了心脏病学奖学金。
- Stuart Rich has served as Chief Medical Officer since January 2021 and a director since February 2021. Dr. Rich joined the Company from PHPM, where he was a co-founder and held the positions of Chief Executive Officer and Director from October 2018 until January 2021. Prior to PHPM, Dr. Rich served as the Chief Medical Officer part-time of United Therapeutics from October 2003 until December 2004. Dr. Rich currently serves as Professor of Medicine at Northwestern University Feinberg School of Medicine and as Director of the Pulmonary Vascular Disease Program at the Bluhm Cardiovascular Institute, a U.K. based charity, and of the Cardiovascular Medical and Research Foundation, a U.S. based charity. Prior to Northwestern University, Dr. Rich was the Professor of Medicine and Chief of the Section of Cardiology at the University of Illinois College of Medicine in Chicago from July 1980 until July 1996 was Professor of Medicine at the Rush Heart Institute of the Rush University School of Medicine from July 1996 until September 2004 and was Professor of Medicine at the Section of Cardiology of the University of Chicago Pritzker School of Medicine from September 2004 until July 2015. Dr. Rich received his B.S. in Biology at the University of Illinois and his M.D. at Loyola University Stritch School of Medicine, and he completed his residency in medicine at the Washington University of St. Louis and his fellowship in cardiology at the University of Chicago.
- Christopher T. Giordano
Christopher T. Giordano，于2021年7月加入公司，担任首席执行官和董事会成员，并于2021年10月成为总裁兼首席执行官。2018年3月至2021年7月，他担任艾昆纬 Biotech LLC和艾昆纬 MedTech Inc.（一家为医疗器械和小型生物技术公司提供临床和商业综合解决方案的供应商）的总裁，在那里他领导了一个管理临床试验组合的高管团队，在他领导的三年中，该团队管理的临床试验组合从250个活跃项目增长到400个活跃项目。在担任该职务之前，2008年8月至2018年3月，佐丹奴先生在医药外包服务提供商Quintiles Transnational Holdings Inc.（于2016年10月被IMS Health Holdings，Inc.收购，更名为艾昆纬控股有限公司）担任越来越重要的职务，最近担任心血管、肾脏和代谢组的全球副总裁。2001年1月至2008年7月，佐丹奴先生在全球临床研究组织PPD，Inc.担任过各种销售和运营职务。佐丹奴先生拥有圣地亚哥大学的英语学士学位（优等生）和北卡罗来纳大学教堂山分校的英语硕士学位。
Christopher T. Giordano joined the Company as Chief Executive Officer and a member of Board of Directors in July 2021 and became President and Chief Executive Officer in October 2021. From March 2018 to July 2021, he served as President of IQVIA Biotech LLC and IQVIA MedTech Inc., a provider of integrated clinical and commercial solutions to medical device and small biotech companies, where he led an executive team that managed a clinical trial portfolio of several hundred active projects during his three years of leadership. Prior to that role, from Augt 2008 to March 2018, Mr. Giordano held roles of increasing responsibility at Quintiles Transnational Holdings Inc., a provider of pharmaceutical outscing services (acquired by IMS Health Holdings, Inc. in October 2016 to become IQVIA Holdings Inc.), and was most recently Global Vice President of the cardiovascular, renal, and metabolic group. From January 2001 to July 2008, Mr. Giordano served in vario sales and operational roles at PPD, Inc., a global clinical research organization. Mr. Giordano holds a B.A. (summa cum laude) in English from the University of San Diego and a M.A. in English from the University of North Carolina at Chapel Hill.- Christopher T. Giordano，于2021年7月加入公司，担任首席执行官和董事会成员，并于2021年10月成为总裁兼首席执行官。2018年3月至2021年7月，他担任艾昆纬 Biotech LLC和艾昆纬 MedTech Inc.（一家为医疗器械和小型生物技术公司提供临床和商业综合解决方案的供应商）的总裁，在那里他领导了一个管理临床试验组合的高管团队，在他领导的三年中，该团队管理的临床试验组合从250个活跃项目增长到400个活跃项目。在担任该职务之前，2008年8月至2018年3月，佐丹奴先生在医药外包服务提供商Quintiles Transnational Holdings Inc.（于2016年10月被IMS Health Holdings，Inc.收购，更名为艾昆纬控股有限公司）担任越来越重要的职务，最近担任心血管、肾脏和代谢组的全球副总裁。2001年1月至2008年7月，佐丹奴先生在全球临床研究组织PPD，Inc.担任过各种销售和运营职务。佐丹奴先生拥有圣地亚哥大学的英语学士学位（优等生）和北卡罗来纳大学教堂山分校的英语硕士学位。
- Christopher T. Giordano joined the Company as Chief Executive Officer and a member of Board of Directors in July 2021 and became President and Chief Executive Officer in October 2021. From March 2018 to July 2021, he served as President of IQVIA Biotech LLC and IQVIA MedTech Inc., a provider of integrated clinical and commercial solutions to medical device and small biotech companies, where he led an executive team that managed a clinical trial portfolio of several hundred active projects during his three years of leadership. Prior to that role, from Augt 2008 to March 2018, Mr. Giordano held roles of increasing responsibility at Quintiles Transnational Holdings Inc., a provider of pharmaceutical outscing services (acquired by IMS Health Holdings, Inc. in October 2016 to become IQVIA Holdings Inc.), and was most recently Global Vice President of the cardiovascular, renal, and metabolic group. From January 2001 to July 2008, Mr. Giordano served in vario sales and operational roles at PPD, Inc., a global clinical research organization. Mr. Giordano holds a B.A. (summa cum laude) in English from the University of San Diego and a M.A. in English from the University of North Carolina at Chapel Hill.
- Thomas A. McGauley
Thomas A. McGauley于2024年12月加入公司担任临时首席财务官。Danforth Advisors，LLC的麦克高利先生是一位高级生命科学财务主管，在金融、生命科学公司、SEC报告和筹资方面拥有广泛的背景。自2021年7月以来，麦高利先生一直是Danforth Advisors，LLC的成员，为多家上市公司和私营公司提供高管财务服务。从2018年到2022年，McGauley先生在CBIZ担任董事，从事会计咨询业务。在此之前，2009年至2018年，他曾担任多家公共和私营生命科学公司的首席财务官和顾问，包括Galectin Therapeutics Inc.（纳斯达克：GALT），2012年至2013年担任临时首席财务官，2009年至2012年担任公司财务/会计和SEC顾问。在此之前，他是deCODEGenetics，Inc.的高级财务主管，该公司前身为纳斯达克上市公司。麦高利的金融生涯始于公共会计，曾在多家会计师事务所工作，最近担任普华永道会计师事务所（PricewaterhoeCoopers LLP）的经理，专门研究生命科学和技术公司。在此之前，他是美国陆军军官，后来是MA国民警卫队，结束了作为上尉和连长的军事生涯。麦克高利先生拥有斯通希尔学院会计学学士学位，是马萨诸塞州的一名注册会计师。
Thomas A. McGauley joined the Company as Interim Chief Financial Officer in December 2024. Mr. McGauley of Danforth Advisors, LLC is a senior life sciences financial executive with an extensive background in finance, life science companies, SEC reporting, and fundraising. Since July 2021, Mr. McGauley has been a member of Danforth Advisors, LLC, providing executive financial services to several public and private companies. From 2018 to 2022, Mr. McGauley was a director at CBIZ in their accounting advisory practice. Prior to that, from 2009 to 2018, he served as the chief financial officer and a consultant to several public and private life science companies, including Galectin Therapeutics Inc. (Nasdaq: GALT), where he was the interim chief financial officer from 2012 to 2013 and the company's financial/accounting and SEC consultant from 2009 to 2012. Prior to that, he was a senior financial executive for deCODE genetics, Inc., a formerly Nasdaq listed company. Mr. McGauley began his financial career in public accounting working with several accounting firms, and was most recently a manager at PricewaterhoeCoopers LLP specializing in life sciences and technology companies. Prior to that, he was an officer in the U.S. Army and later the MA National Guard, ending his military career as a captain and company commander. Mr. McGauley holds a B.S.B.A in Accounting from Stonehill College and is a Certified Public Accountant in Massachetts.- Thomas A. McGauley于2024年12月加入公司担任临时首席财务官。Danforth Advisors，LLC的麦克高利先生是一位高级生命科学财务主管，在金融、生命科学公司、SEC报告和筹资方面拥有广泛的背景。自2021年7月以来，麦高利先生一直是Danforth Advisors，LLC的成员，为多家上市公司和私营公司提供高管财务服务。从2018年到2022年，McGauley先生在CBIZ担任董事，从事会计咨询业务。在此之前，2009年至2018年，他曾担任多家公共和私营生命科学公司的首席财务官和顾问，包括Galectin Therapeutics Inc.（纳斯达克：GALT），2012年至2013年担任临时首席财务官，2009年至2012年担任公司财务/会计和SEC顾问。在此之前，他是deCODEGenetics，Inc.的高级财务主管，该公司前身为纳斯达克上市公司。麦高利的金融生涯始于公共会计，曾在多家会计师事务所工作，最近担任普华永道会计师事务所（PricewaterhoeCoopers LLP）的经理，专门研究生命科学和技术公司。在此之前，他是美国陆军军官，后来是MA国民警卫队，结束了作为上尉和连长的军事生涯。麦克高利先生拥有斯通希尔学院会计学学士学位，是马萨诸塞州的一名注册会计师。
- Thomas A. McGauley joined the Company as Interim Chief Financial Officer in December 2024. Mr. McGauley of Danforth Advisors, LLC is a senior life sciences financial executive with an extensive background in finance, life science companies, SEC reporting, and fundraising. Since July 2021, Mr. McGauley has been a member of Danforth Advisors, LLC, providing executive financial services to several public and private companies. From 2018 to 2022, Mr. McGauley was a director at CBIZ in their accounting advisory practice. Prior to that, from 2009 to 2018, he served as the chief financial officer and a consultant to several public and private life science companies, including Galectin Therapeutics Inc. (Nasdaq: GALT), where he was the interim chief financial officer from 2012 to 2013 and the company's financial/accounting and SEC consultant from 2009 to 2012. Prior to that, he was a senior financial executive for deCODE genetics, Inc., a formerly Nasdaq listed company. Mr. McGauley began his financial career in public accounting working with several accounting firms, and was most recently a manager at PricewaterhoeCoopers LLP specializing in life sciences and technology companies. Prior to that, he was an officer in the U.S. Army and later the MA National Guard, ending his military career as a captain and company commander. Mr. McGauley holds a B.S.B.A in Accounting from Stonehill College and is a Certified Public Accountant in Massachetts.
- Thomas A. McGauley
Thomas A. McGauley于2012年3月6日担任首席财务官，在这之前，从2009年开始担任财务与会计部总监。从2005年11月到2010年1月，McGauley先生担任基因解码公司（deCODE genetics）的财务报表部总监，这是一家总部位于冰岛的以前在纳斯达克上市的国际性生命科学公司。在这之前，McGauley先生任职公共会计超过七年，最后担任普华永道会计师事务所（PricewaterhouseCoopers）的经理，从2003年到2005年，他在该公司专注于生命科学公司。他还担任美国陆军（U.S. Army）与马塞诸塞州的国民卫队（Massachusetts National Guard）的上校与连长。McGauley先生是一位注册会计师，并在石山学院（Stonehill College）获得工商管理理学学士学位。
Thomas A. McGauley,became Chief Financial Officer on March 6 2012 and previously since 2009 had been Director of Finance and Accounting. From November 2005 to January 2010 Mr. McGauley was the Director of Financial Reporting at deCODE genetics, a former NASDAQ listed international life sciences company headquartered in Iceland. Mr. McGauley previously spent more than seven years in public accounting, most recently as a manager at PricewaterhouseCoopers, where he specialized in life science companies from 2003 to 2005. He has also served as a Captain and Company Commander in the U.S. Army and Massachusetts National Guard. Mr. McGauley is a Certified Public Accountant and holds a B.S. in Business Administration from Stonehill College.- Thomas A. McGauley于2012年3月6日担任首席财务官，在这之前，从2009年开始担任财务与会计部总监。从2005年11月到2010年1月，McGauley先生担任基因解码公司（deCODE genetics）的财务报表部总监，这是一家总部位于冰岛的以前在纳斯达克上市的国际性生命科学公司。在这之前，McGauley先生任职公共会计超过七年，最后担任普华永道会计师事务所（PricewaterhouseCoopers）的经理，从2003年到2005年，他在该公司专注于生命科学公司。他还担任美国陆军（U.S. Army）与马塞诸塞州的国民卫队（Massachusetts National Guard）的上校与连长。McGauley先生是一位注册会计师，并在石山学院（Stonehill College）获得工商管理理学学士学位。
- Thomas A. McGauley,became Chief Financial Officer on March 6 2012 and previously since 2009 had been Director of Finance and Accounting. From November 2005 to January 2010 Mr. McGauley was the Director of Financial Reporting at deCODE genetics, a former NASDAQ listed international life sciences company headquartered in Iceland. Mr. McGauley previously spent more than seven years in public accounting, most recently as a manager at PricewaterhouseCoopers, where he specialized in life science companies from 2003 to 2005. He has also served as a Captain and Company Commander in the U.S. Army and Massachusetts National Guard. Mr. McGauley is a Certified Public Accountant and holds a B.S. in Business Administration from Stonehill College.